Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2025-03-07 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
IMFINZI IMPROVED EFS IN EARLY-STAGE GASTRIC CANCER
Regulatory Filings
2025-03-07 English
FORM 6-K
Regulatory Filings
2025-03-07 English
Notice of AGM
AGM Information Classification · 99% confidence The document explicitly states it is a "Notice of Annual General Meeting" and mentions that the "Notice of Annual General Meeting 2025 and Shareholders' Circular" has been published and is being despatched to shareholders. It details the date and time of the AGM and lists the business to be conducted, which includes receiving accounts, re-appointing auditors, and approving remuneration reports. This content is directly related to the preparation for and announcement of the Annual General Meeting. Therefore, the appropriate classification is AGM-R (AGM Information). Although it mentions the publication of reports (like the Auditor's Report), the primary purpose of this specific document is the AGM notice itself.
2025-03-07 English
Notice of AGM
AGM Information Classification · 99% confidence The document explicitly states it is the "AstraZeneca Notice of Annual General Meeting 2025 and Shareholders' Circular". It contains the formal Notice of Annual General Meeting (AGM), details about voting procedures, key timings for the meeting, and a Letter from the Chair inviting shareholders to the AGM. This content aligns perfectly with the definition of materials shared during the Annual General Meeting, which is classified as AGM Information (AGM-R). Although it incorporates elements that might be found in other documents (like board changes or remuneration details), the primary purpose and title point directly to the AGM documentation package.
2025-03-07 English
Proxy Form
AGM Information Classification · 100% confidence The document explicitly contains the title 'AstraZeneca PLC: Joining Instructions Annual General Meeting Friday 11 April 2025' and a 'Proxy Form – Annual General Meeting Friday 11 April 2025'. It details instructions on how to join the AGM online, provides a proxy voting form listing resolutions (including receiving accounts, re-appointing auditors, and director elections), and includes explanatory notes for the proxy form. This content is directly related to soliciting shareholder votes and providing information for the Annual General Meeting. Therefore, the classification is AGM-R (AGM Information).
2025-03-07 English
Imfinzi improved EFS in early-stage gastric cancer
Regulatory Filings Classification · 98% confidence The document is a press release dated March 7, 2025, originating from AstraZeneca PLC, identified by the RNS Number (8003Z). It announces positive high-level results from the MATTERHORN Phase III trial regarding the drug Imfinzi for gastric and gastroesophageal junction cancers, detailing improvements in event-free survival (EFS) and overall survival trends. This type of announcement, detailing clinical trial outcomes and drug performance, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, material announcement about clinical data and drug efficacy, it fits best as an Earnings Release (ER) which often includes significant operational/clinical updates, or as a general Regulatory Filing (RNS) if it's not tied to a standard quarterly earnings report. Given the content is a major clinical trial update, which companies often release outside of formal quarterly reports but still as material news, RNS is a strong candidate. However, ERs often contain these types of clinical highlights. Since the document is a formal announcement of material news via RNS, and it is not a full report (like 10-K or IR), nor a presentation (IP), nor a transcript (CT), the most appropriate general category for a material regulatory announcement that isn't explicitly one of the other types is RNS. It is not a Report Publication Announcement (RPA) because it contains the substantive results, not just a notice that a report is available.
2025-03-07 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.